在为期3个月的第一阶段试验中,Novo Nordisk的amycretin证明了13. 1%的减肥潜力;需要进一步的研究才能进行全面的评估. Novo Nordisk's amycretin proves 13.1% weight loss potential in a 3-month Phase I trial; further research required for full assessment.
Novo Nordisk的实验减重药丸Amycretin在第一阶段试验中显示出令人乐观的结果,帮助超重和肥胖者在短短三个月内损失了高达13.1%的体重。 Novo Nordisk's experimental weight-loss pill, amycretin, has shown promising results in a Phase I trial, helping overweight and obese individuals lose up to 13.1% of their body weight in just three months. 药物的作用是模仿调控胃口的荷尔蒙,被发现是安全的和可容忍的,具有轻度到中度的副作用。 The drug works by mimicking hormones that regulate appetite and was found to be safe and tolerable, with mild-to-moderate side effects. 专家们指出,重量损失潜力巨大,需要进一步研究,以充分评估其功效和安全性。 Experts have noted the significant weight loss potential, indicating further studies are needed to fully assess its efficacy and safety.